Symproic®
Drug - Symproic (naldemedine) [Purdue Pharma]
March 2018
Therapeutic Area - Opioid induced constipation
Approval criteria
- Patient is at least 18 years old AND
- Patient is diagnosed with opioid-induced constipation (OIC) related to chronic non-cancer pain AND
- Patient is currently on opioids AND
- Patient has been using opioids for at least 75 days within past 90 days AND
- Patient has not tolerated or has had inadequate response to one-month trials of a stimulant laxative (e.g., bisacodyl; sennosides) AND polyethylene glycol 3350 OR other osmotic laxative (e.g., sorbitol, lactulose, magnesium citrate, magnesium hydroxide, glycerin rectal suppositories) as documented in pharmacy fill history or other documentation indicating fill/refill history if patient is new to Medical Assistance and pharmacy claims data is not readily available AND
- Patient has not tolerated or has had inadequate response to a one-month trial of Amitiza OR
- If patient’s OIC is due to diphenylheptane opioids (e.g., methadone); patient must have failed a one-month trial of Movantik AND
- Patient does not have ANY of the following conditions:
- Known or suspected gastrointestinal obstruction OR
- Pregnancy OR
- Severe hepatic impairment (Child-Pugh Class C)
Quantity limits
34 tablets per 34 days
Questions?
MHCP Provider Call Center 651-431-2700 or 800-366-5411